세계의 종양 용해성 바이러스 면역치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Oncolytic Virus Immunotherapy Market is presumed to reach the market size of nearly USD 975.6 Million by 2032 from USD 166.35 Million in 2023 with a CAGR of 21.72% under the study period 2024-2032.

Oncolytic virus immunotherapy involves genetically modified viruses that target specific cancer cells for infection and destruction of cancer cells while stimulating an anti-tumor immune response. These oncolytic viruses are engineered to replicate within cancer cells, causing cell lysis and releasing tumor antigens, activating the immune system to target and eliminate remaining cancer cells. This approach directly reduces tumor burden and enhances the body's natural immune response against cancer. It is being explored for various cancers, offering a promising complementary treatment to traditional therapies like chemotherapy and radiation, with the potential for improved efficacy and reduced side effects.

MARKET DYNAMICS

The increasing incidence of cancer worldwide has generated a notable demand for innovative and effective treatment options, with oncolytic virus immunotherapy emerging as a promising approach. Genetic engineering and virology advancements have enabled the development of more potent and targeted oncolytic viruses, enhancing their therapeutic efficacy and safety profile. Additionally, growing awareness and acceptance of immunotherapy as a viable cancer treatment are boosting the adoption of oncolytic virus therapies. Robust investment in research and development by pharmaceutical companies and research institutions is accelerating these therapies' clinical trials and commercialization. Regulatory support and fast-tracked approvals for breakthrough therapies are further propelling market growth.

The ability of oncolytic viruses to stimulate a robust immune response against cancer cells, combined with their potential to be used with other treatments, such as checkpoint inhibitors and traditional therapies, is driving their clinical application. Furthermore, collaborations and partnerships between biotech companies and academic institutions foster innovation and expand the therapeutic pipeline. The overall drive towards personalized medicine, where treatments are tailored to individual patient profiles, also supports the growth of the oncolytic virus immunotherapy market. However, potential safety concerns, high development costs, and the complexity of clinical trials and regulatory approvals may hinder the growth of the oncolytic virus immunotherapy market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Oncolytic Virus Immunotherapy Market. The growth and trends of Oncolytic Virus Immunotherapy Market industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Oncolytic Virus Immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Herpes Simplex Virus
• Vaccinia Virus
• Adenovirus
• Reovirus
• Others

By Route of Administration

• Intratumoral
• Intravenous

By Application

• Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• Breast Cancer
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Oncolytic Virus Immunotherapy Market market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Oncolytic Virus Immunotherapy market include Merck & Co. Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics, Oncorus Inc., Replimune Group Inc., Oncolys Biopharma Inc., Sorrento Therapeutics Inc., Oncolytics Biotech Inc., SillaJen Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Herpes Simplex Virus Historic and Forecast Sales By Regions
• 5.4. Vaccinia Virus Historic and Forecast Sales By Regions
• 5.5. Adenovirus Historic and Forecast Sales By Regions
• 5.6. Reovirus Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data Analysis By Route of Administration
• 6.3. Intratumoral Historic and Forecast Sales By Regions
• 6.4. Intravenous Historic and Forecast Sales By Regions

7. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Melanoma Historic and Forecast Sales By Regions
• 7.4. Non-small Cell Lung Cancer (NSCLC) Historic and Forecast Sales By Regions
• 7.5. Pancreatic Cancer Historic and Forecast Sales By Regions
• 7.6. Breast Cancer Historic and Forecast Sales By Regions
• 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET COMPANIES

• 9.1. Oncolytic Virus Immunotherapy Market Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Merck & Co. Inc. (Viralytics Limited)
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Amgen Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Shanghai Sunway Biotech Co. Ltd.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. TILT Biotherapeutics
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Oncorus Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Replimune Group Inc.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Oncolys Biopharma Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Sorrento Therapeutics Inc.
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Oncolytics Biotech Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. SillaJen Inc
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies